[1] Joshua P,Timothy D,Robert L,et al.Best practices for intrathecal drug delivery for pain[J].Neuromodulation:journal of the International Neuromodulation Society,2014,17(4):354~72,discussion 372.
[2] Prager J,Deer T,Levy R,et al.Best practices for intrathecal drug delivery for pain[J].Neuromodula- tion Technol Neural Interface,2014,17(4):354~372 .
[3] 宋学军,樊碧发,万有,等.国际疼痛学会新版疼痛定义修订简析[J].中国疼痛医学杂志,2020,26(09):641~644.
[4] Wang JK.Pain relief by intrathecal injection of serotonin or morphine[J].Ann Anesthesiol Fr,1978,19(5):371~372.
[5] Bolash R,Udeh B,Saweris Y,et al.Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management:a retrospective analysis of 365 patients[J].Neuromodulation Technol Neural Interface,2015,18(2):150~156.
[6] Deer TR,Pope JE,Hanes MC,et al.Intrathecal therapy for chronic pain:a review of morphine and ziconotide as firstline options[J].Pain Med,2019,20(4):784~798.
[7] Hayek SM,Hanes MC.Intrathecal therapy for chronic pain:current trends and future needs[J].Curr Pain Headache Rep,2014,18(1):388.
[8] Webster LR.The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide:a review of the literature[J].Pain Med,2015,16(7):1265~1277.
[9] Krames ES.Intraspinal opioid therapy for chronic nonmalignant pain:current practice and clinical guidelines[J].J Pain Symptom Manage,1996,11(6):333~352.
[10] Pope J,Deer T,Amirdelfan K,et al.The pharmacology of spinal opioids and ziconotide for the treatment of non-cancer pain[J].Curr Neuropharmacol,2017,15(2):206~216.
[11] Deer TR,Pope JE,Hanes MC,et al.Intrathecal therapy for chronic pain:a review of morphine and ziconotide as firstline options[J].Pain Med,2019,20(4):784~798.
[12] Schultz DM,Orhurhu V,Khan F,et al.Patient satisfaction following intrathecal targeted drug delivery for benign chronic pain:results of a single-center survey study[J].Neuromodulation,2020,23(7):1009~1017.
[13] Szczepaniak A,Fichna J,Zielińska M.Opioids in cancer development,progression and metastasis:focus on colorectal cancer[J].Curr Treat Options Oncol,2020,21(1):6.
[14] 章沿锋,杨旖欣,冯智英.鞘内药物输注系统植入术适应证和药物选择的进展[J].中国疼痛医学杂志,2018,24(10):723~728.
[15] 王昆.癌性爆发痛专家共识(2019年版)[J].中国肿瘤临床,2019,46(6):267~271.
[16] Sung YT,Wu JS.The Visual Analogue Scale for Rating,Ranking and Paired-Comparison (VAS-RRP):A new technique for psychological measurement[J].Behav Res Meth,2018,50(4):1694~1715.
[17] Castro MRH,Magill ST,Morshed RA,et al.Facial pain and sensory outcomes following resection of tumors compressing the trigeminal nerve[J].J Neurosurg,2021,136(4):1119~1127.
[18] Fregene E,Lotze P.Severe urinary retention secondary to intrathecal morphine pain pump:A case report[J].Urol Case Rep,2021,40:101935.
[19] Ballantyne Jc,carwood cM. comparative efficacy of epidural,subarachnoid,and intracerebroventricular opi- oids in patients with pain due to cancer[J].cochrane Database syst Rev,2005,(1):cD005178.
[20] van Dongen RT,Crul BJ,van Egmond J.Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients[J].Clin J Pain,1999,15(3):166~172.
[21] 刘红军,高献忠,李伟彦,等.鞘内注射右旋美托咪啶对晚期癌痛患者行吗啡鞘内镇痛的影响[J].中国疼痛医学杂志,2014,20(6):412~415+420.
[22] Rui D,Sue C,Sarah N,et al.Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain:A Systematic Review and Meta-Analysis[J].Neuromodulation:journal of the International Neuromodulation Society,2022,26(6):1126~1141. |